Objective: To determine the impact of first trimester combined screening (FTS) (nuchal translucency and biochemistry) on the gestational age (GA) at diagnosis for fetal chromosome abnormalities (CA): Down Syndrome (DS), Trisomy 13 (T13), Trisomy 18 (T18), and Turner’s Syndrome (TS), and timing of pregnancy termination. Methods: The Mount Sinai Prenatal Diagnosis Unit database was reviewed to ascertain all referrals for genetic termination over a 3 year period, specifically the number of women carrying fetuses with DS, T13, T18, and TS. The data were examined in relation to the year of diagnosis, availability of FTS, and the GA at diagnosis and termination. Results: Of the 496 women referred for genetic termination over the study period, 172 (34.7%) had CA. Of those with CA, 108 (62.8%) had fetuses with DS, 16 (9.3%) with T13, 37 (21.5%) with T18, and 11 (6.4%) with TS. There was no difference in the number of terminations for CA between 2000 and 2002, however, there was a reduction in the mean GA at termination for all studied CA (Table 1). Table 1